Even though we are further along in trials than Tony stated in the Sky Business interview, I’m sure this will be a trigger for investors to look into Dimerix & have the pleasant surprise that we are actually going into 2b for DMX-200.
The article on 7 news was fantastic. It gave a really good snapshot of kidney disease & the success of DMX-200 in treating CKD, and the future benefits: That DMX-200 may prevent many patients from having to go onto dialysis in the first place & improving length and quality of life for people suffering from kidney disease.
The drug is expected to be on the market within 2 years! Maybe sooner with FDA orphan drug designation?
Even though we are further along in trials than Tony stated in...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.025(6.67%) |
Mkt cap ! $25.68M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 35.0¢ | $387.8K | 1.079M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 394907 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 15948 | 1 |
View Market Depth
| Last trade - 16.10pm 12/12/2024 (20 minute delay) ? |
| DXB (ASX) Chart |